LOS ANGELES, CA – VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has appointed Raju Willener as chief financial officer, effective immediately. Willener, who brings over thirty years of international financial leadership experience, will report to CEO and Co-Founder Christoph Antz, Ph.D. His appointment is expected to bolster the company’s capital strategy and support the continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
Willener’s extensive career spans global capital markets, investment banking, corporate finance, asset management, and strategic leadership. Prior to joining VERAXA, he served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives and financial strategy. Earlier, he held senior executive and investment positions overseeing investment portfolios exceeding CHF 30 billion in assets under management.
The move comes as VERAXA advances its pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL) and is focused on bringing transformative antibody-based therapeutics to patients.
Willener’s appointment is a critical step for VERAXA as it seeks to navigate the complex landscape of biotechnology financing and strategic growth. His expertise in capital markets and corporate finance will be instrumental in advancing the company’s BiTAC platform and oncology pipeline. According to the press release, Willener is expected to support the company’s capital strategy and explore strategic opportunities.
This leadership change underscores the importance of financial stewardship in the biotech sector, where securing funding is paramount to advancing research and development. VERAXA’s commitment to developing next-generation cancer therapies requires substantial investment, and Willener’s track record in managing large-scale portfolios and leading financial strategies positions him well to guide the company through its next phase of growth.
For more information on VERAXA Biotech and its pipeline, visit the company’s newsroom at https://ibn.fm/VRXA.
This appointment also comes at a time when the biotech industry faces significant challenges, including regulatory hurdles and market volatility. Having a seasoned CFO like Willener could provide VERAXA with the financial acumen needed to navigate these complexities and capitalize on emerging opportunities.
The company’s forward-looking statements in the press release remind stakeholders of the inherent risks and uncertainties in drug development and commercialization. However, the strategic addition of Willener to the executive team signals confidence in the company’s direction and its ability to execute on its vision.
For the full press release, visit https://nnw.fm/jcHOU. To learn more about VERAXA Biotech and its proprietary BiTAC technology, visit the company’s website or follow its updates in the newsroom.
